UNA

RNAi drugs startup Arcturus Therapeutics this week announced that it has raised $5 million in a Series A round of financing, which comes just months after the company pulled in $1.5 million in seed money.

Startup Arcturus Therapeutics this week announced that it has acquired Marina Biotech’s unlocked nucleobase analog intellectual property in a move the company said would give it freedom to operate in the RNAi drugs space.

Tekmira Pharmaceuticals last week announced that it has acquired a worldwide, non-exclusive license to Marina Biotech's unlocked nucleobase analog technology, which is used to design RNAi payloads.

Marina Biotech this week announced that the Intellectual Property Office of New Zealand said it will grant the company a patent covering its unlocked nucleobase analog technology.

"We've established the intellectual property portfolio and basis to be an integrated personalized medicine company focused in nucleic acid therapeutics and diagnostics," President and CEO Michael French told Gene Silencing News.

Under the new arrangement, MDRNA is no longer obligated to make any future payments to RiboTask, which retains the rights to make, sell, and sublicense the UNA technology for research and diagnostic purposes.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.